55 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday.
Summit Insights Group Downgrades Qorvo to Hold
Summit Insights Group analyst Kinngai Chan downgrades Qorvo (NASDAQ:QRVO) from Buy to Hold.
Rosenblatt Maintains Neutral on Qorvo, Lowers Price Target to $190
Rosenblatt analyst Kevin Cassidy maintains Qorvo (NASDAQ:QRVO) with a Neutral and lowers the price target from $215 to $190.
24 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Evaxion Biotech A/S (NASDAQ: EVAX) rose 143.5% to $15.83 in pre-market trading after dropping over 10% on Wednesday.
Oppenheimer Maintains Outperform on Qorvo, Lowers Price Target to $220
Oppenheimer analyst Rick Schafer maintains Qorvo (NASDAQ:QRVO) with a Outperform and lowers the price target from $250 to $220.
Wells Fargo Maintains Overweight on Qorvo, Lowers Price Target to $220
Wells Fargo analyst Gary Mobley maintains Qorvo (NASDAQ:QRVO) with a Overweight and lowers the price target from $230 to $220.
Qorvo Q2 EPS $3.42 Beats $3.25 Estimate, Sales $1.25B Beat $1.25B Estimate
Qorvo (NASDAQ:QRVO) reported quarterly earnings of $3.42 per share which beat the analyst consensus estimate of $3.25 by 5.23 percent. This is a 40.74 percent increase over earnings of $2.43 per share from the same
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
Mizuho Downgrades Qorvo to Neutral, Lowers Price Target to $175
Mizuho analyst Vijay Rakesh downgrades Qorvo (NASDAQ:QRVO) from Buy to Neutral and lowers the price target from $220 to $175.